ArticleJapanese journal of clinical oncology2026
Current pharmacological and non-pharmacological approaches to chemotherapy-induced peripheral neuropathy and association with awareness of clinical guidelines.
Article in Japanese journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundChemotherapy-induced peripheral neuropathy (CIPN) is a persistent and challenging adverse event of cancer treatment. This study aimed to describe current pharmacological and non-pharmacological approaches to CIPN and to examine their association with awareness of the Japanese clinical guideline (CIPN-GL2023).
methodsAn online survey was distributed to healthcare professionals involved in CIPN management, including physicians, pharmacists, and nurses. Participants reported whether they recommended pharmacological and non-pharmacological interventions for prevention and treatment.
resultsAmong 450 valid responses, 31% recommended pharmacological prevention, whereas 89% and 97% recommended pharmacological treatment for numbness and pain, respectively. Non-pharmacological strategies were recommended by 57% for prevention and 55% for treatment. Participants who were aware of the guideline were less likely to recommend pharmacological prevention and more likely to implement non-pharmacological prevention and treatment. Duloxetine, pregabalin, and mirogabalin (gabapentinoids) were commonly recommended across prevention and treatment. Guideline awareness was significantly associated with the recommendation of duloxetine for pain (65% vs. 44%, P < .01). Exercise and cryotherapy were frequently recommended for prevention, and exercise was the predominant non-pharmacological treatment. Exercise for prevention was more common as a first-line approach among guideline-aware respondents (56% vs. 35%, P = .02). Pharmacists demonstrated significantly higher guideline awareness, while nurses more frequently adopted non-pharmacological therapies.
conclusionsAwareness of CIPN-GL2023 was associated with increased evidence-based practice, particularly through the use of duloxetine for pain and exercise for prevention. Multidisciplinary engagement and targeted efforts to reduce non-recommended practices remain important for improving CIPN management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.